君实生物
TopAlliance

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the "Shanghai Junshi Biosciences Co., Ltd.* 2021 Third Quarterly Report" published by Shanghai Junshi Biosciences Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for reference purpose only. The unaudited financial data set out in this announcement is prepared in accordance with the accounting principles of the People's Republic of China instead of the International Financial Reporting Standards, and is prepared pursuant to the requirements of the STAR Market of the Shanghai Stock Exchange only. The following is a translation of the 2021 Third Quarterly Report of the Company solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 29 October 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing and Dr. Yao Sheng as executive Directors; Dr. Wu Hai, Mr. Tang Yi, Mr. Li Cong and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Jiang Hualiang and Dr. Roy Steven Herbst as independent non-executive Directors

* *For identification purposes only*

Company code: 688180 Abbreviation: Junshi Bio

Shanghai Junshi Biosciences Co., Ltd.*
2021 Third Quarterly Report

The board (the "Board") of directors (the "Directors") of the Company and all Directors undertake that the information in this announcement does not contain any false record, misleading statement or material omissions, and assume liabilities as to the truthfulness, accuracy and completeness of the contents in this announcement.

Important:

The Board, the Board of Supervisors and the Directors, supervisors and senior management of the Company undertake that the information in this quarterly report is true, accurate and complete and contains no false record, misleading statement or material omissions, and assume several and joint liabilities to the information in this report.

The person in charge of the Company, the person in charge of accounting affairs, and the person in charge of the accounting office (head of accounting department), hereby guarantee that the financial statements contained in this quarterly report are true, accurate and complete.

Whether the financial statements contained in this third quarterly report have been audited
☐Yes √No

I. Key financial data

(I) Key accounting data and financial indicators

Unit: Yuan Currency: RMB

Items	During the reporting period	Changes year-on-year (%)	From the beginning of the year to the end	Changes year-on-year (%)

			of the reporting period	
Operating income	603,948,191.95	38.52	2,718,396,641.58	168.90
Net loss attributable to shareholders of the Company	-401,473,542.90	N/A	-392,126,592.23	N/A
Net loss attributable to the shareholders of the Company after deducting non-recurring profit and loss	-420,932,635.47	N/A	-534,263,254.34	N/A
Net cash flow from operating activities	N/A	N/A	-540,121,393.81	N/A
Basic earnings per share (yuan/share)	-0.44	N/A	-0.44	N/A
Diluted earnings per share (yuan/share)	-0.44	N/A	-0.44	N/A
Weighted average return on net assets (%)	-5.10	Increased by 4.98 percentage points	-6.12	Increased by 26.52 percentage points
Total research and development investment	475,292,923.98	-5.16	1,422,572,326.73	17.56
Research and development investment as a percentage of operating income (%)	78.70	Decreased by 36.24 percentage points	52.33	Decreased by 67.37 percentage points
	As at the end of the reporting period	As at the end of the previous year		Increase/decrease at the end of the reporting period compared with the end of the previous year (%)
Total assets	9,591,447,499.18	7,997,409,506.14		19.93

Owner's equity attributable to the shareholders of the Company	7,693,139,705.30	5,827,808,532.40	32.01

Note: "the reporting period" refers to the period of three months commencing from the beginning of this quarter to the end of this quarter, same as below.

(II) Non-recurring gains and losses items and amounts

Unit: Yuan Currency: RMB

Items	Amount for the reporting period	Amount for the period commencing from the beginning of the year to the end of the reporting period
Gains or losses from the disposal of non-current assets (including those written off by providing for impairment on assets)	-3,983.46	772,770.80
Government grants that are recognized in profit or loss for the period (other than government grants which are closely related to the Company's normal business operations, which comply with national policies and enjoyed continuously at fixed amount or quantity in accordance with a certain standards)	9,088,364.88	35,138,705.83
Profit or loss from changes in fair value from holding of financial assets held for trading and financial liabilities held for trading, investment income from disposal of financial assets held for trading, financial liabilities held for trading and financial assets available for sale, except for effective hedging transactions related to the Company's normal business operations	17,073,267.28	142,125,974.77
Other non-operating income and expenses apart from the aforesaid items	-7,153,128.38	-23,710,802.01
Less: Effect of income tax	-454,572.25	12,189,987.28
Total	19,459,092.57	142,136,662.11

Description on defining the non-recurring gains or losses items set out in the Explanatory Announcement No. 1 for Information Disclosure for Companies Publicly Issuing Securities –

Non-recurring Gains or Losses Items as recurring gains or losses items
☐Applicable √Not applicable

(III) Descriptions and reasons for changes in major accounting data and financial indicators
√Applicable ☐Not applicable

Items	Changes (%)	Major reasons
Operating income_ During the reporting period	38.52	Mainly due to the significant increase in the out-licensing income and the income generated from new royalty fee during the reporting period.
Basic earnings per share (yuan/share) _ During the reporting period	N/A	Mainly due to the significant increase in the operating income, which results in a decrease in the loss.
Diluted earnings per share (yuan/share) _ During the reporting period	N/A	Mainly due to the significant increase in the operating income, which results in a decrease in the loss.
Research and development investment as a percentage of operating income (%)_During the reporting period	Decreased by 36.24 percentage points	Mainly due to the significant increase in the out-licensing income, which results in a significant increase in the operating income, the percentage has decreased accordingly.
Operating income_From the beginning of the year to the end of the reporting period	168.90	Mainly due to the income generated from new royalty fee and the significant increase in the out-licensing income from the beginning of the year to the end of the reporting period.
Net loss attributable to shareholders of the Company_From the beginning of the year to the end of the reporting period	N/A	Mainly due to the significant increase in the operating income, which results in a decrease in the loss.
Net loss attributable to the shareholders of the Company after deducting non-recurring profit and loss_From the beginning of the year to the end of the reporting period	N/A	Mainly due to the significant increase in the operating income, which results in a decrease in the loss.

Net cash flow from operating activities_From the beginning of the year to the end of the reporting period	N/A	Mainly due to the significant increase in the out-licensing income, which results in a increase in the cash inflows and a decrease in the net cash outflows.
Basic earnings per share (yuan/share) _From the beginning of the year to the end of the reporting period	N/A	Mainly due to the significant increase in the operating income, which results in a decrease in the loss.
Diluted earnings per share (yuan/share) _From the beginning of the year to the end of the reporting period	N/A	Mainly due to the significant increase in the operating income, which results in a decrease in the loss.
Research and development investment as a percentage of operating income (%)_From the beginning of the year to the end of the reporting period	Decreased by 67.37 percentage points	Mainly due to the significant increase in the out-licensing income, which results in a significant increase in the operating income, the percentage has decreased accordingly.
Owner's equity attributable to the shareholders of the Company_From the beginning of the year to the end of the reporting period	32.01	Mainly due to the new H shares issued on 23 June 2021, which results in a significant increase in the share premium.

II. Shareholder Information

(I) Particulars of total number of ordinary shareholders and preference shareholders with voting rights restored and shareholding of top ten shareholders

Unit: Share

Total number of ordinary shareholders as at the end of the reporting period	33,127	Total number of preference shareholders with voting rights restored as at the end of the reporting period, if any	N/A
Particulars of shareholding of the top ten shareholders			

Name of shareholder	Nature of shareholder	Number of shares held	Shareholding percentage (%)	Number of shares held subject to trading restrictions	Number of restricted shares including lending shares for securities financing	Shares pledged, marked or frozen	
						Status of shares	Number of shares
HKSCC NOMINEES LIMITED	Unknown	219,292,630	24.08	0	0	Unknown	-
Xiong Jun	Domestic natural person	87,252,968	9.58	87,252,968	87,252,968	Nil	0
Shanghai Tanying Investment Partnership (LP)* (上海檀英投资合伙企业(有限合伙))	Other	76,590,000	8.41	0	0	Nil	0
Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)* (苏州瑞源盛本生物医药管理合伙企业(有限合伙))	Other	43,584,000	4.79	43,584,000	43,584,000	Nil	0
Xiong Fengxiang	Domestic natural person	41,060,000	4.51	41,060,000	41,060,000	Nil	0
Zhou Yuqing	Domestic natural person	21,680,800	2.38	21,680,800	21,680,800	Nil	0
Shi Wen	Domestic natural person	17,531,997	1.92	0	0	Nil	0
Wang Zhenhua	Domestic natural person	16,515,000	1.81	0	0	Nil	0
Wang Shujun	Domestic natural person	15,814,256	1.74	0	0	Pledged	6,580,000

Feng Hui	Domestic natural person	13,140,000	1.44	13,140,000	13,140,000	Nil	0

Particulars of shareholdings of the top ten Shareholders not subject to trading restrictions

Name of Shareholder	Number of tradable shares held not subject to trading restrictions	Type and number of shares	
		Type of shares	Number of shares
HKSCC NOMINEES LIMITED	219,292,630	Overseas listed foreign shares	219,292,630
Shanghai Tanying Investment Partnership (LP)* (上海檀英投资合伙企业(有限合伙))	76,590,000	RMB ordinary shares	7,659,000
Shi Wen	17,531,997	RMB ordinary shares	17,531,997
Wang Zhenhua	16,515,000	RMB ordinary shares	16,515,000
Wang Shujun	15,814,256	RMB ordinary shares	15,814,256
Zhang Jun	12,750,000	RMB ordinary shares	12,750,000
Jin Mingzhe	12,024,000	RMB ordinary shares	12,024,000
Huang Fei	9,840,036	RMB ordinary shares	9,840,036
Lepu Medical Technology (Beijing) Co., Ltd.* (乐普（北京）医疗器械股份有限公司)	8,235,122	RMB ordinary shares	8,235,122
ICBC Credit Suisse – ICBC wealth management products under the class of private placement – ICBC Credit Suisse Investment– Junshengdan – asset management scheme (工银瑞信投资－中国工商银行私募股权类专项理财產品－工银瑞信投资－君生单一资产管理计划)	7,600,000	RMB ordinary shares	7,600,000
Explanation on the	Among the above shareholders, Xiong Fengxiang and Xiong Jun are father and son and		

related party relationship or acting-in-concert arrangement among the above shareholders	are the controlling shareholders and actual controllers of the Company. Xiong Jun, Xiong Fengxiang are acting in concert with Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)* (苏州瑞源盛本生物医药管理合伙企业(有限合伙)) (hereinafter referred to as "Ruiyuan Shengben") and Zhou Yuqing. Xiong Jun holds 40% of the equity interest in Shenzhen Qianhai Yuanben Equity Investment Fund Management Co., Ltd.* (深圳前海源本股权投资基金管理有限公司), Ruiyuan Shengben's managing partner. Ruiyuan Shengben is held as to 6.96%, 5.1% and 1.39% by Jin Mingzhe, Zhou Yuqing and Huang Fei, respectively. Zhang Jun and Huang Fei are spouse. Other than the above explanation, the Company is not aware whether the other Shareholders have related party relationship or whether the other Shareholders are acting-in-concert parties under relevant regulations.
Description on the top ten shareholders and the top ten shareholders not subject to trading restrictions engaging in margin trading and securities financing, if any	Among the above shareholders, Shi Wen holds 10,066,985 shares of the Company through ordinary securities account and 7,465,012 shares through margin account, which renders a total of 17,531,997 shares of the Company. Zhang Jun holds 8,750,000 shares of the Company through ordinary securities account and 4,000,000 shares through margin account, which renders a total of 12,750,000 shares of the Company. Huang Fei holds 4,590,036 shares of the Company through ordinary securities account and 5,250,000 shares through margin account, which renders a total of 9,840,036 shares of the Company.

Note 1: As at the end of the reporting period, among all the ordinary shareholders, there are 33,120 A Shares shareholders and 7 H Shares shareholders, totaling 33,127 shareholders;

Note 2: HKSCC NOMINEES LIMITED holds shares on behalf of various customers.

III. Other Significant Information

Other significant information about the operational results of the Company during the reporting period that requires investors' attention

☐Applicable √Not applicable

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Types of audit opinion

☐Applicable √Not applicable

(II) Financial statement

CONSOLIDATED BALANCE SHEET

30 September 2021

Prepared by: Shanghai Junshi Biosciences Co., Ltd.*

Unit: Yuan Currency: RMB Audit type: Unaudited

Items	30 September 2021	31 December 2020
Current assets:		
Cash and bank balances	3,147,459,500.68	3,384,997,561.89
Held-for-trading financial assets	17,298.96	17,102.05
Notes receivable	49,869,548.75	74,115,760.11
Accounts receivable	697,007,243.24	590,324,155.59
Prepayments	469,253,728.91	258,178,283.57
Other receivables	29,516,826.48	22,840,431.36
Including: Interests receivable	-	-
Dividends receivable	-	-
Inventories	401,447,647.29	343,425,428.27
Non-current assets due within one year	2,317,231.33	3,524,807.19
Other current assets	60,981,518.75	21,293,154.01
Total current assets	4,857,870,544.39	4,698,716,684.04
Non-current assets:		
Long-term equity investments	258,519,356.12	66,171,419.68
Other equity instruments investments	259,715,931.33	-
Other non-current financial assets	771,939,976.91	356,724,866.15
Fixed assets	1,915,147,555.02	1,905,914,113.97
Construction in progress	605,039,421.17	415,550,140.47
Right-of-use-assets	110,474,295.57	55,169,735.03
Intangible assets	164,084,345.94	162,088,048.23
Long-term prepaid expenses	27,156,999.27	13,236,525.11
Deferred tax assets	84,367,168.91	26,112,859.60
Other non-current assets	537,131,904.55	297,725,113.86
Total non-current assets	4,733,576,954.79	3,298,692,822.10
Total assets	9,591,447,499.18	7,997,409,506.14
Current liabilities:		
Short-term borrowings	541,666.67	21,234,648.29
Notes payable	232,680.00	-
Accounts payable	868,927,487.38	797,697,494.08
Contract liabilities	74,605,517.88	43,142,036.14
Employee benefits payable	124,812,143.78	205,025,983.28
Taxes payable	33,260,970.07	19,619,540.34
Other payables	39,332,546.45	129,413,494.77

Including: Interests payable	-	-
Dividends payable	-	-
Non-current liabilities due within one year	39,339,736.45	256,331,193.26
Other current liabilities	9,522,373.91	-
Total current liabilities	1,190,575,122.59	1,472,464,390.16
Non-current liabilities:		
Long-term borrowings	490,000,000.00	542,222,222.23
Lease liabilities	90,597,530.68	30,991,342.99
Expected liabilities	1,280,411.10	1,280,411.10
Deferred income	112,675,400.97	103,808,732.94
Other non-current liabilities	13,183,043.36	18,837,294.77
Total non-current liabilities	707,736,386.11	697,140,004.03
Total liabilities	1,898,311,508.70	2,169,604,394.19
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	910,756,700.00	872,496,000.00
Capital reserve	10,827,891,445.66	8,632,380,276.66
Other comprehensive income	14,293,424.98	-9,392,471.15
Retained earnings	-4,059,801,865.34	-3,667,675,273.11
Total owners' equity (or shareholders' equity) attributable to equity holders of the Company	7,693,139,705.30	5,827,808,532.40
Minority interests	-3,714.82	-3,420.45
Total owners' equity (or shareholders' equity)	7,693,135,990.48	5,827,805,111.95
Total liabilities and equity	9,591,447,499.18	7,997,409,506.14

Legal Representative: Xiong Jun Chief Financial Officer: Xu Baohong Head of Accounting Department: Cai Jingwu

CONSOLIDATED INCOME STATEMENT

January to September 2021

Prepared by: Shanghai Junshi Biosciences Co., Ltd.*

Unit: Yuan Currency: RMB Audit type: Unaudited

Items	First three quarters of 2021 (January to September)	First three quarters of 2020 (January to September)
1. Total operating income	2,718,396,641.58	1,010,928,016.06

Including: Operating income	2,718,396,641.58	1,010,928,016.06
2. Total operating costs	3,138,462,309.55	2,134,265,536.78
Including: Operating costs	750,100,610.99	208,713,827.52
Taxes and surcharges	5,059,716.69	4,872,434.71
Selling and distribution expenses	527,443,356.23	417,485,839.22
Administrative expenses	428,191,758.80	276,805,181.35
Research and development expenses	1,422,572,326.73	1,210,046,361.83
Financial expenses	5,094,540.11	16,341,892.15
Including: Interest expenses	26,921,129.50	18,758,681.30
Interest income	24,991,682.09	9,823,050.18
Add: Other income	35,138,705.83	14,102,759.84
Investment income (Loss is indicated by “-”)	-31,949,820.39	-7,339,887.61
Including: Income from investments in associates and joint ventures	-32,735,573.81	-4,892,963.61
Income from changes in fair value (Loss is indicated by “-”)	141,340,221.35	26,623,824.50
Impairment loss of credit (Loss is indicated by “-”)	418,787.06	-229,868.75
Impairment loss of assets (Loss is indicated by “-”)	-14,231,351.81	-2,442,057.58
Income from disposal of assets (Loss is indicated by “-”)	805,981.39	-
3. Operating profit (Loss is indicated by “-”)	-288,543,144.54	-1,092,622,750.32
Add: Non-operating income	46,951.73	2,242,064.65
Less: Non-operating expenses	23,790,964.33	37,801,553.45
4. Total profit (Total loss is indicated by “-”)	-312,287,157.14	-1,128,182,239.12

Less: Income tax expenses	79,839,729.45	-12,516,733.44
5. Net profit (Net loss is indicated by "-")	-392,126,886.59	-1,115,665,505.68
(I) Categorized by the nature of continuing operation		
1. Net profit from continuing operations (Net loss is indicated by "-")	-392,126,886.59	-1,115,665,505.68
2. Net profit from discontinued operations (Net loss is indicated by "-")	-	-
(II) Categorized by ownership		
1. Net profit attributable to the owners of the Company (Net loss is indicated by "-")	-392,126,592.23	-1,115,665,017.00
2. Profit or loss attributable to minority interests (Net loss is indicated by "-")	-294.36	-488.68
6. Other comprehensive income, net of tax	23,685,896.13	-8,680,818.02
(I) Other comprehensive income attributable to the owners of the Company, net of tax	23,685,896.13	-8,680,818.02
1. Other comprehensive income that cannot be subsequently reclassified to profit or loss	25,595,074.18	-
(1) Changes of the re-measurement in defined benefit plans	-	-
(2) Other comprehensive income that cannot be subsequently reclassified to profit or loss under the equity method	-	-
(3) Changes in fair value of other equity instruments	25,595,074.18	

investments		
(4) Changes in fair value of the enterprise's own credit risk	-	-
2. Other comprehensive income that will be reclassified to profit or loss	-1,909,178.05	-8,680,818.02
(1) Other comprehensive income that will be transferred to profit or loss under the equity method	-	-
(2) Changes in fair value of other debt investments	-	-
(3) Amount of financial assets that are reclassified to other comprehensive income	-	-
(4) Impairment provision for credit of other debt investments	-	-
(5) Cash flow hedge reserves	-	-
(6) Translation differences of financial statements denominated in foreign currencies	-1,909,178.05	-8,680,818.02
(II) Other comprehensive income attributable to minority interests, net of tax	-	-
7. Total comprehensive income	-368,440,990.46	-1,124,346,323.70
(I) Total comprehensive income attributable to owners of the Company	-368,440,696.10	-1,124,345,835.02
(II) Total comprehensive income attributable to minority interests	-294.36	-488.68
8. Earnings per share:		
(I) Basic earnings per share (yuan/share)	-0.44	-1.39

(II) Diluted earnings per share (yuan/share)	-0.44	-1.39

For the business combination under common control occurs during the current period, net profit of the acquiree realized before business combination was nil. Net profit of the acquiree realized during the last period was nil.

Legal Representative: Xiong Jun Chief Financial Officer: Xu Baohong
Head of Accounting Department: Cai Jingwu

CONSOLIDATED STATEMENT OF CASH FLOWS

January to September 2021

Prepared by: Shanghai Junshi Biosciences Co., Ltd.*

Unit: Yuan Currency: RMB Audit type: Unaudited

Items	First three quarters of 2021 (January to September)	First three quarters of 2020 (January to September)
1. Cash flows from operating activities:		
Cash receipts from the sale of goods and the rendering of services	2,584,764,961.17	825,237,852.23
Receipts of tax refunds	72,362,699.32	60,186,286.64
Other cash receipts relating to operating activities	60,669,882.28	29,171,227.89
Sub-total of cash inflows from operating activities	2,717,797,542.77	914,595,366.76
Cash payments for goods purchased and services received	2,265,344,173.44	1,366,017,982.22
Cash payments to and on behalf of employees	844,140,353.20	496,233,638.54
Payments of various types of taxes	22,576,748.00	17,553,625.86
Other cash payments relating to operating activities	125,857,661.94	129,474,522.88
Sub-total of cash outflows from operating activities	3,257,918,936.58	2,009,279,769.50
Net cash flows from operating activities	-540,121,393.81	-1,094,684,402.74

II. Cash flow from investing activities:		
Cash receipts from disposals and recovery of investments	303,990,009.53	106,388.00
Cash receipts from investment income	785,753.42	-
Net cash receipts from disposal of fixed assets, intangible assets and other long-term assets	873.07	-
Other cash receipts relating to investing activities	24,991,682.09	9,823,050.18
Sub-total of cash inflows from investing activities	329,768,318.11	9,929,438.18
Cash payments to acquire or construct fixed assets, intangible assets and other long-term assets	660,708,467.91	374,155,040.64
Cash payments to acquire investments	1,105,268,305.29	10,000,000.00
Other cash payments relating to investing activities	20,000,000.00	72,630,960.56
Sub-total of cash outflows from investing activities	1,785,976,773.20	456,786,001.20
Net cash flows from investing activities	-1,456,208,455.09	-446,856,563.02
III. Cash flows from financing activities:		
Cash receipts from investors	2,121,734,262.98	4,526,365,587.50
Including: Cash receipts from capital contributions by minority interests of subsidiaries	-	-
Cash receipts from borrowings	500,000,000.00	354,238,589.36
Other cash receipts relating to financing activities	-	19,245,833.33
Sub-total of cash inflows from financing activities	2,621,734,262.98	4,899,850,010.19
Cash repayments of borrowings	793,333,333.34	374,749,734.75
Cash payments for distribution of dividends, or profits or settlement of interest expenses	27,614,111.12	34,067,181.79
Including: Cash payments for distribution of dividends or profits to	-	-

minority interests of subsidiaries		
Other cash payments relating to financing activities	30,774,685.44	32,589,160.15
Sub-total of cash outflows from financing activities	851,722,129.90	441,406,076.69
Net cash flows from financing activities	1,770,012,133.08	4,458,443,933.50
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-11,220,345.39	-13,285,059.54
V. Net increase in cash and cash equivalents	-237,538,061.21	2,903,617,908.20
Add: Balance of cash and cash equivalents at the beginning of the period	3,384,997,561.89	1,214,025,879.93
VI. Balance of cash and cash equivalents at the end of the period	3,147,459,500.68	4,117,643,788.13

Legal Representative: Xiong Jun Chief Financial Officer: Xu Baohong
Head of Accounting Department: Cai Jingwu

(II) Particulars in relation to adjustments made to relevant items of the financial statements as at the beginning of the year of the initial adoption of new lease standard in 2021

☐Applicable √Not applicable

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

30 October 2021

* *For identification purpose only*